FcγRII (CD32) modulates antibody clearance in NOD SCID mice leading to impaired antibody-mediated tumor cell deletion

BACKGROUND: Immune compromised mice are increasingly used for the preclinical development of monoclonal antibodies (mAb). Most common are non-obese diabetic (NOD) severe combined immunodeficient (SCID) and their derivatives such as NOD SCID interleukin-2 γ-/- (NSG), which are attractive hosts for pa...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:J Immunother Cancer
Main Authors: Oldham, Robert J, Mockridge, C Ian, James, Sonya, Duriez, Patrick J, Chan, H T Claude, Cox, Kerry L, Pitic, Vicentiu A, Glennie, Martin J, Cragg, Mark S
פורמט: Artigo
שפה:Inglês
יצא לאור: BMJ Publishing Group 2020
נושאים:
Basic Tumor Immunology
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC7304853/
https://ncbi.nlm.nih.gov/pubmed/32554613
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-000619
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים